Technological Pathways to Produce Compressed and Highly Pure Hydrogen from Solar Power

Hydrogen (H2) produced from renewables will have a growing impact on the global energy dynamics towards sustainable and carbon-neutral standards. The share of green H2 is still too low to meet the net-zero target, while the demand for high-quality hydrogen continues to rise. These factors amplify the need for economically viable H2 generation technologies. The present article aims at evaluating the existing technologies for high-quality H2 production based on solar energy. Technologies such as water electrolysis, photoelectrochemical and solar thermochemical water splitting, liquid metal reactors and plasma conversion utilize solar power directly or indirectly (as carbon-neutral electrons) and are reviewed from the prospective of their current development level, technical limitations and future potential.

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study

Background

The aim of the RESGEX study was to compare the efficacy and safety of the anti-epidermal growth factor receptor (anti-EGFR) antibody tomuzotuximab against cetuximab both in combination with chemotherapy in patients with recurrent and/or metastatic squamous cell cancer of the head and neck in the first-line treatment.

Patients and methods

In this phase II trial 240 patients were equally randomized for six cycles to receive either tomuzotuximab (initial dose 990 mg then 720 mg) weekly and cisplatin 100 mg/m² and fluorouracil (5-FU; 1000 mg/m²/day, days 1-4) every 3 weeks or cetuximab (400 mg/m² subsequent 250 mg/m²) weekly with the same chemotherapeutic backbone followed by antibody maintenance treatment. The primary endpoint was progression-free survival.

Results

Median progression-free survival was 6.5 months [95% confidence interval (CI) 5.9-7.9 months] in the tomuzotuximab group and 6.2 months (95% CI 5.8-7.3 months) in the cetuximab group (P = 0.86). The median overall survival (OS) estimate was 11.6 months (95% CI 9.5-17.2 months) in the tomuzotuximab group and 13.8 months (95% CI 12.3-16.4 months) in the cetuximab group (P = 0.96). In an exploratory analysis a small subgroup of p16-positive patients had a significantly longer OS compared with p16-negative patients (hazard ratio 1.860, 95% CI 1.09-3.16, P = 0.02).

Conclusions

The glyco-engineered antibody tomuzotuximab failed to demonstrate improved efficacy with a chemotherapeutic backbone in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. It remains a so far unanswered question whether such antibody would partner better with different drugs such as checkpoint inhibitors.

•

Tomuzotuximab has a potential higher antibody-dependent cell cytotoxicity than other EGFR-directed antibodies.

•

Comparison of two anti-EGFR antibodies combined with chemotherapy in patients with squamous cell cancer of head and neck.

•

Efficacy, safety, and tolerability of tomuzotuximab and cetuximab in combination with chemotherapy were similar.

Mono-planar T-Hex: Speed and flexibility for high-resolution 3D imaging

Purpose

The aim of this work is the reconciliation of high spatial and temporal resolution for MRI. For this purpose, a novel sampling strategy for 3D encoding is proposed, which provides flexible k‐space segmentation along with uniform sampling density and benign filtering effects related to signal decay.

Methods

For time‐critical MRI applications such as functional MRI (fMRI), 3D k‐space is usually sampled by stacking together 2D trajectories such as echo planar imaging (EPI) or spiral readouts, where each shot covers one k‐space plane. For very high temporal and medium to low spatial resolution, tilted hexagonal sampling (T‐Hex) was recently proposed, which allows the acquisition of a larger k‐space volume per excitation than can be covered with a planar readout. Here, T‐Hex is described in a modified version where it instead acquires a smaller k‐space volume per shot for use with medium temporal and high spatial resolution.

Results

Mono‐planar T‐Hex sampling provides flexibility in the choice of speed, signal‐to‐noise ratio (SNR), and contrast for rapid MRI acquisitions. For use with a conventional gradient system, it offers the greatest benefit in a regime of high in‐plane resolution <1 mm. The sampling scheme is combined with spirals for high sampling speed as well as with more conventional EPI trajectories.

Conclusion

Mono‐planar T‐Hex sampling combines fast 3D encoding with SNR efficiency and favorable depiction characteristics regarding noise amplification and filtering effects from T2∗ decay, thereby providing flexibility in the choice of imaging parameters. It is attractive both for high‐resolution time series such as fMRI and for applications that require rapid anatomical imaging.

3-Dimensional JEG-3 choriocarcinoma cell organoids as a model for trophoblast expansion and differentiation

JEG-3 choriocarcinoma cells have been widely used as a model for placental trophoblast. Herein, 3-dimensional (3D) JEG-3 organoids (JEG-3-ORGs) were established using a protocol that we recently developed for primary cytotrophoblast organoids (CTB-ORGs). 3D JEG-3-ORGs, cultivated in basic culture medium, rapidly divide and spontaneously undergo differentiation. Under stem cell culture conditions (activation of WNT/EGF signalling and inhibition of TGF-β signalling) smaller organoids with reduced proliferative capacity were generated specifically abolishing expression of extravillous trophoblast (EVT)-specific genes. Similar to CTB-ORGs, removal of the WNT activator CHIR99021 induced re-expression of these genes in JEG-3-ORGs. Hence, JEG-3-ORGs could be used as a model for directed EVT differentiation.

T-Hex: Tilted hexagonal grids for rapid 3D imaging

PURPOSE

The purpose of this work is to devise and demonstrate an encoding strategy for 3D MRI that reconciles high speed with flexible segmentation, uniform k-space density, and benign T 2 ∗ effects.

METHODS

Fast sampling of a 3D k-space is typically accomplished by 2D readouts per shot using EPI trains or spiral readouts. Tilted hexagonal (T-Hex) sampling is a way of acquiring more k-space volume per excitation while maintaining uniform sampling density and a smooth T 2 ∗ filter. The k-space volume covered per shot is controlled by the tilting angle. Image reconstruction is performed with a 3D extension of the iterative SENSE approach, incorporating actual field dynamics and static off-resonance. T-Hex imaging is compared with established 3D schemes in terms of speed and noise performance.

RESULTS

Tilted hexagonal acquisition is found to achieve greater imaging speed than known alternatives, particularly in combination with spiral trajectories. The interplay of the proposed 3D trajectories, array detection, and off-resonance is successfully addressed by iterative inversion of the full signal model. Enhanced coverage per shot is of greatest utility for high speed in an intermediate resolution regime of 1 to 4 mm. T-Hex EPI combines the benefits of extended coverage per shot with increased robustness against off-resonance effects.

CONCLUSION

Sampling of tilted hexagonal grids is a feasible means of gaining 3D imaging speed with near-optimal SNR efficiency and benign depiction properties. It is a particularly promising technique for time-resolved applications such as fMRI.

Echo-planar imaging of the human head with 100 mT/m gradients and high-order modeling of eddy current fields

PURPOSE

To demonstrate the utility of a high-performance gradient insert for ultrafast MRI of the human head.

METHODS

EPI was used for the first time with a readout gradient amplitude of 100 mT/m, 1200 T/m/s slew rate, and nearly 1 MHz signal bandwidth for human head scanning. To avoid artefacts due to eddy currents, the magnetic field was dynamically monitored with NMR probes at multiple points, modeled by solid harmonics up to fifth order, and included in the image reconstruction. An approximation of a negligible intra-echo effect of the eddy currents was made to accelerate the high-order reconstruction. The field monitoring-based approach was compared with a recently proposed phase error estimation from separate reconstructions of even and odd echoes.

RESULTS

Images obtained with the gradient insert have significantly lower distortions than it is the case with the whole body 30 mT/m, 200 T/m/s gradients of the same system. However, eddy currents of high spatial order must be properly characterized and corrected for in order to avoid a persistent 2D Nyquist ghost. Multi-position monitoring proves to be a robust method to measure the eddy currents and allows higher undersampling rates than the image-based approach. The proposed approximation of the eddy currents effect allows a significant acceleration of the high-order reconstruction by a separate processing of each spatial dimension.

CONCLUSION

Strong gradients with adequate switching rates are highly beneficial for the quality of EPI provided that robust measures are taken to include the contribution of eddy currents to the image encoding.

Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

Essentials ADAMTS-13-deficiency is a cause of thrombotic thrombocytopenic purpura (TTP). Preclinical safety of recombinant human ADAMTS-13 (BAX930) was shown in animal models. Preclinical efficacy of BAX930 was shown in a mouse model of TTP. BAX930 showed advantageous efficacy over fresh frozen plasma, the current standard of care. Click to hear Dr Cataland and Prof. Lämmle present a seminar on Thrombotic Thrombocytopenic Purpura (TTP): new Insights in Pathogenesis and Treatment Modalities.

SUMMARY

Background Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by microthrombosis in small blood vessels of the body, resulting in a low platelet count. Baxalta has developed a new recombinant ADAMTS-13 (rADAMTS-13) product (BAX930) for on-demand and prophylactic treatment of patients with hereditary TTP (hTTP). Objectives To evaluate the pharmacokinetics, efficacy and safety of BAX930 in different species, by use of an extensive preclinical program. Methods The prophylactic and therapeutic efficacies of BAX930 were tested in a previously established TTP mouse model. Pharmacokinetics were evaluated after single intravenous bolus injection in mice and rats, and after repeated dosing in cynomolgus monkeys. Toxicity was assessed in rats and monkeys, safety pharmacology in monkeys, and local tolerance in rabbits. Results BAX930 was shown to be efficacious, as demonstrated by a stabilized platelet count in ADAMTS-13 knockout mice that were thrombocytopenic when treated. Prophylactic efficacy was dose-dependent and comparable with that achieved by treatment with fresh frozen plasma, the mainstay of hTTP treatment. Therapeutic efficacy was treatment interval-dependent. Safety pharmacology evaluation did not show any deleterious effects of BAX930 on cardiovascular and respiratory functions in monkeys. The compound's pharmacokinetics were similar and dose-proportional in mice, rats, and monkeys. BAX930 was well tolerated in rats, monkeys, and rabbits, even at the highest doses tested. Conclusions These results demonstrate that BAX930 has a favorable preclinical profile, and support the clinical development of rADAMTS-13 for the treatment of hTTP.

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

BACKGROUND

A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity.

PATIENTS AND METHODS

Seventy-four patients with advanced TA-MUC1-positive carcinomas received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week in doses of 1-2200 mg in a three-plus-three dose-escalation design until disease progression (NCT01222624).

RESULTS

No maximum tolerated dose was reached. Adverse events were mainly mild-to-moderate infusion-related reactions (IRRs) by the first infusion in 45% of patients. Only one dose-limiting toxicity, a grade III IRR, was observed. PankoMab-GEX exhibited linear PK over all doses. Mean terminal half-life was 189 ± 66 h (Q3W), without dose dependency. A target trough level ≥50 μg/mL was reached after one infusion with doses ≥1700 mg Q3W in 80% of patients. Clinical benefit in 60 evaluable patients included one complete response in a patient with ovarian cancer treated 483 d and confirmed disease stabilisation in 19 patients lasting a median (range) of 23 (10-109) weeks. All but two of the patients with clinical benefit had received a compounded total dose ≥700 mg over a 3-week period, including 8 of 12 (67%) patients with ovarian cancer.

CONCLUSION

PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.

[Hippocampal stroke]

Unilateral cerebral ischemia of the hippocampus is very rare. This paper reviews the literature and presents the case of a 59-year-old woman with an amnestic syndrome due to a left hippocampal stroke. The patient suffered from retrograde amnesia which was most severe over the 2 days prior to presenting and a slight anterograde amnesia. In addition, a verbal memory disorder was confirmed 1 week after admission by neurological tests. As risk factors, arterial hypertension and a relative hyper-beta lipoproteinemia were found. This case shows that unilateral amnestic stroke, e.g. in the hippocampus region, may be the cause of an amnestic syndrome and should be included in the differential diagnostics.

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study

BACKGROUND

Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. The objective of the study was to explore the efficacy, safety and tolerability of vidofludimus in steroid-dependent inflammatory bowel disease (IBD).

METHODS

The open label uncontrolled ENTRANCE study (ClinicalTrials.gov NCT00820365) has been conducted at 13 study centers in Germany, Bulgaria and Romania. Thirty-four steroid-dependent patients with a confirmed diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) were treated with a once daily 35mg oral dose of vidofludimus over 12weeks. Steroids were tapered during the first 8weeks followed by a steroid-free treatment period of 4weeks. Complete response was defined as steroid-free clinical remission at week 12; partial response was defined as being in remission at steroid dose equal or lower than the individual patient's threshold dose for relapse.

RESULTS

Of the thirty-four patients enrolled in this trial 26 were evaluable for primary efficacy assessment. After completion of the 12weeks treatment phase 8 out of 14 (57.1%) patients with CD and 6 out of 12 (50.0%) patients with UC were in steroid-free remission (complete responders). Another 4 (28.6%) patients in CD and 5 (41.7%) patients in UC were partial responders. Vidofludimus was well tolerated, no drug-related serious adverse events were observed.

CONCLUSIONS

This trial provides first evidence of clinical efficacy of vidofludimus in IBD. Although the safety and tolerability profile seems favorable, long-term controlled studies are needed to further investigate its potential as novel IBD therapy.

Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination

In the recent pandemic influenza A-(H1N1) v-2009 vaccination campaign, adjuvanted vaccines have been used because of their antigen-sparing effect. According to available reports, the rate of severe vaccination reactions has not increased, as compared with previous seasonal influenza vaccinations. Here we describe an adult female patient who was vaccinated with an AS03 adjuvanted split-virus vaccine injected into the left arm. She experienced a prolonged and painful local reaction for 4 weeks. During this time, persistent incapacitating pain shifted into the left shoulder. Magnetic resonance imaging (MRI) at the injection site detected atraumatic humeral head osteonecrosis in conjunction with bursitis of the rotator cuff region. Clinical and laboratory examination revealed no other underlying disease. Using analgetic medication and physical therapy, resting pain completely remitted within the following 14 weeks. Pain on exertion declined within the following 6 months. Atraumatic osteonecrosis, a relatively rare disorder which initially presents non-specific clinical symptoms, has never been associated with parenteral influenza vaccination. Although the available data cannot establish a causal relationship, our patient's clinical course - with a continuous transition from increased local post-vaccination reactions to symptoms of a severe shoulder lesion with osteonecrosis - raises the question of a pathogenetic link. Considering the vascular pathogenesis of osteonecrosis, we hypothesize that our patient's enhanced local immunologic reaction may have led to regional vasculitis as the cause of bone destruction. As mild forms of osteonecrosis may have escaped previous clinical attention, it is the purpose of our report to increase awareness of this exceptional event as a possible side effect of parenteral adjuvanted vaccination.

Thermally induced radical hydrosilylation for synthesis of C18 HPLC phases from highly condensed SiH terminated silica surfaces

Silicon hydride terminated silica surfaces were prepared at high temperatures by a chlorination-reduction sequence. SiH groups are desired for further surface modification as an alternative to the native silanol groups which are unfavorable for RPLC applications. Only few silanol groups remain in these materials and mostly SiH moieties with the highest degree of cross-linking are obtained. The retention properties of basic analytes on the SiH terminated material confirm that the surfaces is mostly free of silanols and that therefore the remaining SiOH groups are bulk species. A reagentless, radical initiated hydrosilylation reaction is introduced for the functionalization of the hydride terminated surface with 1-octadecene. (13)C CP/MAS NMR and DRIFT spectroscopy demonstrate the reaction of the carbon-carbon double bond and the SiH group as well as the linkage of C18 groups to the silica surface. These novel C18 materials show promising performance in RPLC separation, especially for the separation of organic bases.

Characterization of bixin by LC-MS and LC-NMR

An overview upon modern analytical techniques for the isolation, separation, and structural identification of the essential bioactive carotenoid bixin is given. Isolation from biological matrices is performed by matrix solid phase dispersion (MSPD). The extract is separated with shape-selective C(30 )columns. Structural assignment of the separated compounds is done by online LC-MS and capillary HPLC-NMR.

Preparation of a mercaptopropyl bonded silica intermediate in supercritical carbon dioxide: Synthesis, characterisation and chromatography of a quinine based chiral stationary phase

This research examines the preparation of a mercaptopropyl bonded silica intermediate in supercritical carbon dioxide (sc-CO(2)) and the subsequent conversion in sc-CO(2) to a quinine derived chiral stationary phase (CSP). The effects of reaction temperature, pressure and time on the surface coverage of the silica intermediate were investigated when porous silica particles (Exsil-Avanti, 3microm) were reacted with 3-trimethoxymercaptopropylsilane in sc-CO(2). We present results which demonstrate that a stable mercaptopropyl bonded silica intermediate can be successfully prepared under supercritical conditions of 40 degrees C, 483bar, in a substantially reduced reaction time of 1h with superior surface coverages compared to organic solvent based methods. The further utility of this supercritical fluid technology was demonstrated by the free radical addition of a quinine derived chiral selector onto a mercaptopropyl bonded silica intermediate in sc-CO(2). This supercritical fluid generated chiral stationary phase (CSP) was utilised for the direct LC enantioseparation of a series of 3,5-dinitrobenzoyl (DNB) amino acids. Bonded silica samples were characterised using elemental analysis, diffuse reflectance infrared fourier transform (DRIFT) spectroscopy, solid state (13)C and (29)Si CP-MAS NMR spectroscopy, and thermogravimetric analysis (TGA). This supercritical fluid functionalisation approach offers an efficient and cleaner alternative to existing organic solvent based approaches for the preparation of bonded silica phases.

Sympatry and allopatry in two desert ant sister species: how do Cataglyphis bicolor and C. savignyi coexist?

Two extremely morphologically similar sister species of desert ants, Cataglyphis bicolor and C. savignyi, exhibit broadly overlapping distributional ranges within Tunisia. In order to analyse the microhabitats of C. bicolor and C. savignyi within the sympatric and allopatric areas of both ant species, the plant species located at 113 different nest sites of the two ant species were determined. In the sympatric area, the two species exhibit a clear-cut nest site segregation. This is not the case in the allopatric areas. Hence the two species differentiate their microhabitat only when they are sympatric. The plant species associated mainly with the nest sites of C. bicolor indicate that this species prefers a type of vegetation that needs irrigation. This is in contrast to the nest sites of C. savignyi, which are usually found around plants that characterize typical dry steppe areas. As the ants' foraging paths recorded in the sympatric area reveal, C. bicolor performs significantly shorter foraging runs with respect to both length and time, and covers a much smaller foraging range than C. savignyi does. This result reflects the fact that the microhabitat occupied by the colonies of C. bicolor is richer in food abundance. When direct interspecific interactions were investigated by placing a bait midway between two heterospecific nests, C. bicolor foragers dominated over those of C. savignyi. The same dominance of C. bicolor over C. savignyi occurred in laboratory experiments. These results suggest that the dominant species drives the subordinate one out of the high quality microhabitats, and that the subordinate species is forced to survive in the less lucrative habitats. In conclusion, coexistence seems to be maintained by the asymmetric competitive relationship between the two species and the fact that the subordinate species has the ability to endure in the less favourable microhabitat.

Ludwig Rehn (1849-1930)--pioneering findings on the aetiology of bladder tumours

One hundred and six years ago, the surgeon Ludwig Rehn from Frankfurt am Main held a pioneering lecture in Berlin about the possible origins of bladder tumours. He thereby gave the decisive impulse for cancer research in general and specifically for the investigation of aetiological factors involved in the development of urogenital tract tumours. Thereafter, this resulted in an intensified scientific discussion addressing this issue. Although the detailed evaluation of the causes finally contributing to tumour growth is still ongoing, the work of Ludwig Rehn on bladder tumours among aniline workers considerably promoted the establishment of urology as a specialised field within German clinical medicine and is therefore a milestone in the history of medicine.